AI powered precision Guardant Health’s focus on precision medicine and AI analytics for cancer insights creates a sales opportunity to offer integrated data analytics services, real-world evidence partnerships, and AI-driven test optimization for biopharma collaborators and healthcare systems seeking personalized treatment strategies.

IP landscape awareness Recent IP litigation and royalties related to sequencing technology indicate a need for alternative or complementary diagnostic platforms, sequencing methods, or licensing opportunities for customers seeking robust, non-infringing assays and diversified supplier options.

Companion diagnostics With a record quarterly companion diagnostics revenue showing growth, there is a clear opportunity to cross-sell or expand collaborations with pharma companies for custom biomarker tests and co-developed diagnostic solutions aligned to new oncology therapies.

Global expansion needs Guardant Health serves a large oncology market with a substantial revenue base; sales teams can target biopharma sponsors, hospital networks, and international markets for scale, including reference laboratories, CLIA-certified partners, and regional distribution strategies.

Data and outcomes Leverage Guardant’s real-world data capabilities and ELK-based analytics to offer data-driven outcomes research, payer value demonstrations, and health economics studies to convince healthcare systems and payers of the value of early detection, monitoring, and precision treatment strategies.